Harmony Biosciences Holdings (HRMY) EBIT (2019 - 2026)

Harmony Biosciences Holdings has disclosed EBIT across 8 years of filings, most recently posting $8.3 million for Q1 2026.

• EBIT for Q1 2026 came in at $8.3 million, down 85.18% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.7 million (down 101.41% YoY), and the FY2025 annual result was $45.2 million, down 76.33% from the prior year.
• EBIT came in at $8.3 million for Q1 2026 at Harmony Biosciences Holdings, up from -$124.7 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $65.5 million in Q3 2025 to a low of -$124.7 million in Q4 2025.
• The 5-year median for EBIT is $46.9 million (2023), against an average of $32.7 million.
• Across the five-year window, EBIT jumped 442.05% in 2023 and slumped 323.86% in 2025, its largest moves.
• Harmony Biosciences Holdings' EBIT stood at $47.6 million in 2022, then slipped by 15.58% to $40.2 million in 2023, then soared by 38.64% to $55.7 million in 2024, then plunged by 323.86% to -$124.7 million in 2025, then soared by 106.68% to $8.3 million in 2026.
• The last three EBIT figures came in at $8.3 million (Q1 2026), -$124.7 million (Q4 2025), and $65.5 million (Q3 2025), per Business Quant data.